Overview

Full Product Details

9780367576912

Table of Contents

Reviews

""This important book is relevant because this type of trial is preferred when an approved treatment is available and a conventional placebo-controlled trial would be difficult to justify. These trials are complex and this book goes a long way toward helping the investigator with the issues that arise. … This book is comprehensive and includes extensive coverage of every topic. It includes both frequentist and Bayesian approaches as appropriate. Throughout every chapter, topics are fully explained and examples are completely worked out, including statistical formulas and results. … a modern and thorough compendium for anyone involved in the design and analysis of noninferiority trials."" —Mark Bailey, Technometrics, November 2014 ""… it offers unique perspectives and insights from three renowned experts in clinical trials who work at the U.S. Food and Drug Administration (FDA) and in the pharmaceutical industry. It is refreshing to see FDA and industry perspectives blended thoughtfully, as in this book. … Written clearly and concisely, the book is a pleasure to read. Although there are some technical discussions intended for statisticians, most of the book is readily accessible to medical researchers with little statistical training. We recommend the book to anyone interested in NI trials—statisticians and nonstatisticians alike."" —Zhiwei Zhang and Lei Nie, Journal of the American Statistical Association, March 2014 ""It is a pleasure to see a book completely devoted to the challenging arena of non-inferiority trials. … I am very impressed with its depth and breadth, and believe that it will be an important resource for anyone involved in designing non-inferiority trials. The authors weave in many examples, primarily in oncology, as well as a large set of references from the now substantial statistical literature on non-inferiority designs. … This book is a must-have resource for those involved in non-inferiority trials for the

This important book is relevant because this type of trial is preferred when an approved treatment is available and a conventional placebo-controlled trial would be difficult to justify. These trials are complex and this book goes a long way toward helping the investigator with the issues that arise. ... This book is comprehensive and includes extensive coverage of every topic. It includes both frequentist and Bayesian approaches as appropriate. Throughout every chapter, topics are fully explained and examples are completely worked out, including statistical formulas and results. ... a modern and thorough compendium for anyone involved in the design and analysis of noninferiority trials. -Mark Bailey, Technometrics, November 2014 ... it offers unique perspectives and insights from three renowned experts in clinical trials who work at the U.S. Food and Drug Administration (FDA) and in the pharmaceutical industry. It is refreshing to see FDA and industry perspectives blended thoughtfully, as in this book. ... Written clearly and concisely, the book is a pleasure to read. Although there are some technical discussions intended for statisticians, most of the book is readily accessible to medical researchers with little statistical training. We recommend the book to anyone interested in NI trials-statisticians and nonstatisticians alike. -Zhiwei Zhang and Lei Nie, Journal of the American Statistical Association, March 2014 It is a pleasure to see a book completely devoted to the challenging arena of non-inferiority trials. ... I am very impressed with its depth and breadth, and believe that it will be an important resource for anyone involved in designing non-inferiority trials. The authors weave in many examples, primarily in oncology, as well as a large set of references from the now substantial statistical literature on non-inferiority designs. ... This book is a must-have resource for those involved in non-inferiority trials for the

This important book is relevant because this type of trial is preferred when an approved treatment is available and a conventional placebo-controlled trial would be difficult to justify. These trials are complex and this book goes a long way toward helping the investigator with the issues that arise. ... This book is comprehensive and includes extensive coverage of every topic. It includes both frequentist and Bayesian approaches as appropriate. Throughout every chapter, topics are fully explained and examples are completely worked out, including statistical formulas and results. ... a modern and thorough compendium for anyone involved in the design and analysis of noninferiority trials. -Mark Bailey, Technometrics, November 2014 ... it offers unique perspectives and insights from three renowned experts in clinical trials who work at the U.S. Food and Drug Administration (FDA) and in the pharmaceutical industry. It is refreshing to see FDA and industry perspectives blended thoughtfully, as in this book. ... Written clearly and concisely, the book is a pleasure to read. Although there are some technical discussions intended for statisticians, most of the book is readily accessible to medical researchers with little statistical training. We recommend the book to anyone interested in NI trials-statisticians and nonstatisticians alike. -Zhiwei Zhang and Lei Nie, Journal of the American Statistical Association, March 2014 It is a pleasure to see a book completely devoted to the challenging arena of non-inferiority trials. ... I am very impressed with its depth and breadth, and believe that it will be an important resource for anyone involved in designing non-inferiority trials. The authors weave in many examples, primarily in oncology, as well as a large set of references from the now substantial statistical literature on non-inferiority designs. ... This book is a must-have resource for those involved in non-inferiority trials for the pharmaceutical industry, and a must-read for those new to non-inferiority trials. A portion of a special topics course in a biostatistics department could be built around this book, and this exposure would be especially valuable for students considering a career in or around the pharmaceutical industry. -Erica Brittain, Australian & New Zealand Journal of Statistics, May 2012 This is the first book which is devoted solely to non-inferiority studies. All three authors have published several papers on that topic over the last years. This comprehensive book covers in more than 400 pages nearly all aspects about non-inferiority trials, and beyond. It is also an excellent source of references about non-inferiority studies. ... recommended for anyone working with clinical trials and in particular for those working in late phase drug development. It is an excellent source of concepts and statistical methods relevant for biostatisticians, clinical epidemiologists and students. This book also is a good source for non-inferiority studies for scientists from the clinical field. -Steffen Witte, Journal of Biopharmaceutical Statistics, 2012

Author Information

Dr. Mark Rothmann earned his Ph. D. in Statistics at the University of Iowa. He taught several years as a professor and has worked at the U. S. Food and Drug Administration. He has done research in many areas involving the design and analysis of clinical trials. Dr. Brian L. Wiens, received his MS in statistics from Colorado State University and his Ph.D. in statistics from Temple University. He has worked at several pharmaceutical, biotechnology and medical device companies since 1991. He has published research in several areas of design and analysis of clinical trials. Dr. Wiens is a Fellow of the American Statistical Association. Dr. Ivan S.F. Chan received his M.S. in Statistics from The Chinese University of Hong Kong and his Ph.D. in Biostatistics from University of Minnesota. He has worked at Merck Research Laboratories since 1995 and is currently Senior Director and Franchise Head for vaccines, leading the statistical support for all vaccine clinical research programs at Merck. Dr. Chan has published research in many areas of statistics including exact inference, analysis of non-inferiority trials, and methodologies for clinical trials.

Tab Content 6

Customer Reviews

Recent Reviews

Countries Available